I am a life sciences executive with more than 30 years of operational and investment experience. Throughout my career, I have created eight pharma businesses and a royalty/credit focused investment business that has raised over $5bn. I have also been personally involved in over $4bn in healthcare financings, including growth equity, public equity turnarounds, structured debt and royalty acquisitions. I have also led, structured and closed over 40 additional IP licenses, as well as royalty-debt deals and have restructured and turned around multiple private and public companies.With insight from pharmaceutical industry commercial and operational roles, exceptional deal-making experience and an understanding of capital markets, I partner with life science experts to realize value in assets that have high potential, are emerging, have been undercapitalized, misunderstood or undervalued. This strategy allows me to consistently achieve exceptional value and investor returns. My early roles at Abbot Laboratories and Elan Pharmaceuticals gave me excellent operational experience in healthcare technology. Moving to Private Equity and my time with Apax Partners represented a steep learning curve as well as a pivotal stage in my career. I instigated the firm’s entry into the specialty pharmaceutical sector and commercial stage investing; highlights included average equity returns of greater than 40% IRR in primary deals associated with new investment areas. Since then, I’ve been at the vanguard of innovation and growth in the industry, with extensive experience across both development and commercial-stage business investments. Subsequent to Apax, I co-founded Healthcare Royalty Partners and Royalty Rx Capital and have pioneered project and royalty finance in the biopharmaceutical sector. Structure is just the tool though - what really matters are assets, science and management. I enjoy working with experienced life science clinicians and executives who are launching, acquiring, or restructuring business ventures with high-potential products and technologies.